Observations on the human rejection behaviour syndrome: Denny-Brown revisited.
The parietal avoiding-rejection behaviour syndrome, first described by Denny-Brown in the rhesus monkey, has been reported only rarely in humans. Here, we describe a patient with rejection behaviour in the setting of progressive cognitive decline accompanied by cortical myoclonus.
Warren
Jason D
JD
Dementia Research Group, Institute of Neurology, Queen Square, London, United Kingdom.
Hu
Michele T M
MTM
National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom.
Galloway
Malcolm
M
Division of Neuropathology, Institute of Neurology, Queen Square, London, United Kingdom.
Greenwood
Richard J
RJ
National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom.
Rossor
Martin N
MN
Dementia Research Group, Institute of Neurology, Queen Square, London, United Kingdom.|National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001284:Atrophy / Q000473:pathology; D001921:Brain / Q000473:pathology; D003072:Cognition Disorders / Q000175:diagnosis; D004359:Drug Therapy, Combination; D006801:Humans; D020363:Limbic Encephalitis / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D010468:Perceptual Disorders / Q000175:diagnosis* / Q000209:etiology; D011239:Prednisolone / Q000627:therapeutic use; D012059:Rejection, Psychology; D014110:Touch / Q000502:physiology*
D000893:Anti-Inflammatory Agents; D011239:Prednisolone; D008775:Methylprednisolone